drugset / Trial / NCT07455734
Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors
Phase 1/2
Recruiting
533 enrolled
BioNTech SE
BioNTech (Shanghai) Pharmaceuticals Co., Ltd. · collabBiotheus (Hengqin) Co., Ltd. · collab
RandomizedSequentialOpen-labelTreatment
Summary
This study is the first time the drug BNT3214 (also referred to as PM8102) will be tested in people. It is designed to find out if the drug is safe and how well it works for adults with advanced solid tumors. The study will have three parts. The first two parts (Parts A and B) will focus on testing different amounts of BNT3214 to figure out the best and safest dose. The third part (Part C) will test selected doses of BNT3214 in multiple types of cancer.
Timeline
- Start
- 2026-03-30
- Primary completion
- 2030-10
- Completion
- 2030-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BNT3214 | Unknown | — | Intravenous |
Indications
No indication recorded.